Paper Details

  1. Home
  2. Paper Details

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Author: BertschUta, BlauIgor W, BosGerard M J, BroylAnnemiek, DuehrsenUlrich, El JarariLaila, GoldschmidtHartmut M, HoseDirk, JauchAnna, KerstenMarie-Jose, LindemannWalter, LokhorstHenk M, PfreundschuhMichael, RaymakersReinier, SalwenderHans, SchaafsmaMartijn R, ScheidChristof, Schmidt-WolfIngo G H, SonneveldPieter, Stevens-KroefMarian, VellengaEdo, WeiselKatja C, WijermansPierre W, WittebolShulamiet, ZweegmanSonja, van Marwijk-KooyMarinus, van der HoltBronno, van der VeldeHelgi

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Bortezomib during induction and maintenance therapy significantly improved complete response rates, progression-free survival, and overall survival in patients with newly diagnosed multiple myeloma.
Paper Details　
Original Abstract of the Article :
PURPOSE: We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). PATIENTS AND METHODS: In all, 827 eligible patients with newly diagnosed symptomatic MM were randomly assigned to receive induction therapy with vincristine, doxo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2011.39.6820

データ提供：米国国立医学図書館（NLM）

Bortezomib: A New Weapon in the Battle Against Multiple Myeloma

Multiple myeloma is a cancer affecting plasma cells, and finding effective treatments is a constant challenge for researchers. This study investigated the efficacy of bortezomib, a proteasome inhibitor, in the treatment of newly diagnosed multiple myeloma. The researchers conducted a phase III clinical trial to compare the effectiveness of bortezomib-based regimens with standard chemotherapy regimens. The study found that bortezomib improved complete response rates and significantly prolonged progression-free survival and overall survival in patients with newly diagnosed myeloma. The benefits were particularly pronounced in high-risk patients with impaired kidney function or specific genetic abnormalities.

A New Oasis in the Desert of Multiple Myeloma

Bortezomib emerged as a beacon of hope in the treatment of multiple myeloma. This proteasome inhibitor, like a refreshing oasis in a desolate desert, significantly improved survival rates, particularly in high-risk patients. The study findings provide strong evidence for the benefits of bortezomib in the management of multiple myeloma.

Bortezomib: A New Hope in the Desert of Multiple Myeloma

The study highlights the potential of bortezomib to improve the lives of patients with multiple myeloma. The drug may help to extend life expectancy and improve quality of life. However, it’s crucial to understand that bortezomib, like any powerful medicine, can have side effects. The research team has provided valuable insights into the benefits and risks associated with this promising treatment.

Dr. Camel's Conclusion

This study provides crucial insights into the use of bortezomib in the treatment of multiple myeloma. It offers hope for patients who are battling this complex disease, like a camel caravan finally reaching a verdant oasis after a long trek through the desert. The research team has provided a valuable tool to help clinicians make informed decisions about the treatment of this disease.

Date :
  1. Date Completed 2012-10-30
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

22802322

DOI: Digital Object Identifier

10.1200/JCO.2011.39.6820

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.